following a full submission:
pembrolizumab (Keytruda®) is not recommended for use within NHSScotland.
Indication under review: in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.
In a phase III, randomised, double-blind study, in patients with resectable, non-small cell lung carcinoma, the addition of neoadjuvant and adjuvant pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival versus the addition of placebo.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2688
- Indication:
In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non‑small cell lung carcinoma at high risk of recurrence in adults.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 November 2024